Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Depreciation & Amortization (CF) (2019 - 2023)

Historic Depreciation & Amortization (CF) for Marker Therapeutics (MRKR) over the last 5 years, with Q1 2023 value amounting to $818216.0.

  • Marker Therapeutics' Depreciation & Amortization (CF) rose 4196.98% to $818216.0 in Q1 2023 from the same period last year, while for Dec 2023 it was $818216.0, marking a year-over-year decrease of 7066.39%. This contributed to the annual value of $2.8 million for FY2022, which is 2978.73% up from last year.
  • Per Marker Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $818216.0 for Q1 2023, which was up 4196.98% from $813110.0 recorded in Q4 2022.
  • Over the past 5 years, Marker Therapeutics' Depreciation & Amortization (CF) peaked at $819883.0 during Q3 2022, and registered a low of $10514.0 during Q1 2019.
  • For the 5-year period, Marker Therapeutics' Depreciation & Amortization (CF) averaged around $373357.0, with its median value being $502743.0 (2021).
  • In the last 5 years, Marker Therapeutics' Depreciation & Amortization (CF) soared by 132561.46% in 2021 and then surged by 934.58% in 2022.
  • Over the past 5 years, Marker Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $34215.0 in 2019, then skyrocketed by 522.29% to $212916.0 in 2020, then skyrocketed by 165.12% to $564488.0 in 2021, then soared by 44.04% to $813110.0 in 2022, then grew by 0.63% to $818216.0 in 2023.
  • Its last three reported values are $818216.0 in Q1 2023, $813110.0 for Q4 2022, and $819883.0 during Q3 2022.